

Technology appraisal (TA)	Date of TA Release	Adherence of local formulary to NICE	
		Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
<b>2022-23</b>			
<a href="#">TA783 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma</a>	13/04/2022	Yes	
<a href="#">TA784 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer</a>	20/04/2022	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA785 - Nivolumab with cabozantinib for untreated advanced renal cell carcinoma</a>	20/04/2022	No	Terminated appraisal
<a href="#">TA786 - Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies</a>	27/04/2022	Yes	
<a href="#">TA787 - Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable</a>	27/04/2022	Yes	
<a href="#">TA788 - Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy</a>	11/05/2022	Yes	
<a href="#">TA789 - Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations</a>	18/05/2022	Yes	
<a href="#">TA790 - TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)</a>	25/05/2022	No	Terminated appraisal
<a href="#">TA791 - Romosozumab for treating severe osteoporosis</a>	25/05/2022	Yes	
<a href="#">TA792 - Filgotinib for treating moderately to severely active ulcerative colitis</a>	01/06/2022	Yes	
<a href="#">TA793 - Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)</a>	08/06/2022	No	Terminated appraisal
<a href="#">TA794 - Diroximel fumarate for treating relapsing-remitting multiple sclerosis</a>	08/06/2022	Yes	
<a href="#">TA795 - Ibrutinib for treating Waldenstrom's macroglobulinaemia</a>	08/06/2022	No	Not recommended
<a href="#">TA796 - Venetoclax for treating chronic lymphocytic leukaemia</a>	15/06/2022	Yes	
<a href="#">TA797 - Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer</a>	15/06/2022	No	Terminated appraisal
<a href="#">TA798 - Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation</a>	22/06/2022	No	Not recommended
<a href="#">TA799 - Faricimab for treating diabetic macular oedema</a>	29/06/2022	Yes	
<a href="#">TA800 - Faricimab for treating wet age-related macular degeneration</a>	29/06/2022	Yes	
<a href="#">TA801 - Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer</a>	29/06/2022	Yes	
<a href="#">TA802 - Cemiplimab for treating advanced cutaneous squamous cell carcinoma</a>	29/06/2022	Yes	
<a href="#">TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs</a>	13/07/2022	Yes	
<a href="#">TA804 - Teduglutide for treating short bowel syndrome</a>	30/06/2022	Yes	
<a href="#">TA805 - Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides</a>	13/07/2022	Yes	
<a href="#">TA806 - Belimumab for treating lupus nephritis</a>	13/07/2022	No	Terminated appraisal
<a href="#">TA807 - Roxadustat for treating symptomatic anaemia in chronic kidney disease</a>	13/07/2022	No	Not applicable to CWFT - Not a commissioned site
<a href="#">TA808 - Fenfluramine for treating seizures associated with Dravet syndrome</a>	08/07/2022	No	Not applicable to CWFT - Not a commissioned site
<a href="#">TA809 - Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease</a>	20/07/2022	No	Not applicable to CWFT - Not a commissioned site
<a href="#">TA810 - Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence</a>	20/07/2022	Yes	
<a href="#">TA811 - Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments</a>	27/07/2022	No	Terminated appraisal

<a href="#">TA812 - Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer</a>	03/08/2022	<b>No</b>	Not recommended
<a href="#">TA813 - Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors</a>	03/08/2022	<b>No</b>	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis</a>	03/08/2022	<b>Yes</b>	
<a href="#">TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs</a>	10/08/2022	<b>Yes</b>	
<a href="#">TA816 - Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer</a>	10/08/2022	<b>Yes</b>	
<a href="#">TA817 - Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence</a>	10/08/2022	<b>Yes</b>	
<a href="#">TA818 - Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma</a>	17/08/2022	<b>Yes</b>	
<a href="#">TA819 - Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies</a>	17/08/2022	<b>Yes</b>	
<a href="#">TA820 Brodalumab for treating diabetic macular oedema</a>	31/08/2022	<b>Yes</b>	
<a href="#">TA821 - Avalglucosidase alfa for treating Pompe disease</a>	24/08/2022	<b>No</b>	Not applicable to CWFT - Not a commissioned site
<a href="#">TA822 Melphalan for haematological disease before allogeneic haematopoietic stem cell transplant</a>	14/09/2022	<b>No</b>	Terminated appraisal
<a href="#">TA823 Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer</a>	28/09/2022	<b>Yes</b>	
<a href="#">TA824 Dexamethasone intravitreal implant for treating diabetic macular oedema</a>	14/09/2022	<b>Yes</b>	
<a href="#">TA825 Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis</a>	21/09/2022	<b>No</b>	Not applicable to CWFT - Not a commissioned site
<a href="#">TA826 Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis</a>	21/09/2022	<b>No</b>	Terminated appraisal
<a href="#">TA827 Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy</a>	05/10/2022	<b>Yes</b>	
<a href="#">TA828 Ozanimod for treating moderately to severely active Ulcerative Colitis</a>	05/10/2022	<b>Yes</b>	
<a href="#">TA829 Upadacitinib for treating active ankylosing spondylitis</a>	30/09/2022	<b>Yes</b>	
<a href="#">TA830 Pembrolizumab for adjuvant treatment of renal cell carcinoma</a>	19/10/2022	<b>No</b>	Not applicable to CWFT - Not a commissioned site
<a href="#">TA831 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer</a>	05/10/2022	<b>Yes</b>	
<a href="#">TA832 Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids</a>	19/10/2022	<b>Yes</b>	
<a href="#">TA833 Zanubrutinib for treating Waldenstrom's macroglobulinaemia</a>	19/10/2022	<b>Yes</b>	
<a href="#">TA834 SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites</a>	12/10/2022	<b>No</b>	Terminated appraisal
<a href="#">TA835 Fostamatinib for treating refractory chronic immune thrombocytopenia</a>	19/10/2022	<b>Yes</b>	
<a href="#">TA836 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</a>	26/10/2022	<b>Yes</b>	
<a href="#">TA837 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma</a>	26/10/2022	<b>Yes</b>	
<a href="#">TA838 Slow-release potassium bicarbonate-potassium citrate for treating distal renal tubular acidosis</a>	02/11/2022	<b>No</b>	Terminated appraisal
<a href="#">TA839 Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids</a>	16/11/2022	<b>No</b>	Terminated appraisal
<a href="#">TA840 Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids</a>	16/11/2022	<b>No</b>	Terminated appraisal
<a href="#">TA841 Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma</a>	22/11/2022	<b>No</b>	Terminated appraisal
<a href="#">TA842 Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies</a>	22/11/2022	<b>No</b>	Terminated appraisal
<a href="#">TA843 Luspatercept for treating anaemia caused by beta-thalassaemia</a>	24/11/2022	<b>No</b>	Terminated appraisal
<a href="#">TA844 Luspatercept for treating anaemia caused by myelodysplastic syndromes</a>	24/11/2022	<b>No</b>	Terminated appraisal
<a href="#">TA845 Mepolizumab for treating eosinophilic granulomatosis with polyangiitis</a>	29/11/2022	<b>No</b>	Terminated appraisal
<a href="#">TA846 Mepolizumab for treating severe hypereosinophilic syndrome</a>	29/11/2022	<b>No</b>	Terminated appraisal

<a href="#">TA847 Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps</a>	29/11/2022	No	Terminated appraisal
<a href="#">TA848 Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer</a>	01/12/2022	No	Terminated appraisal
<a href="#">TA849 Cabozantinib for previously treated advanced hepatocellular carcinoma</a>	14/12/2022	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA850 Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy</a>	14/12/2022	No	Not recommended by NICE
<a href="#">TA851 Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer</a>	14/12/2022	Yes	
<a href="#">TA852 Trifluridine-tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments</a>	14/12/2022	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA853 Avatrombopag for treating primary chronic immune thrombocytopenia</a>	15/12/2022	Yes	
<a href="#">TA854 Esketamine nasal spray for treatment-resistant depression</a>	14/12/2022	No	Not recommended by NICE
<a href="#">TA855 Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy</a>	04/01/2023	Yes	
<a href="#">TA856 Upadacitinib for treating moderately to severely active ulcerative colitis</a>	04/01/2023	Yes	
<a href="#">TA857 Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma</a>	11/01/2023	Yes	
<a href="#">TA858 Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma</a>	11/01/2023	Yes	
<a href="#">TA859 Angiotensin II for treating vasopressor-resistant hypotension caused by septic or distributive shock</a>	16/01/2023	No	Terminated appraisal
<a href="#">TA860 Maribavir for treating refractory cytomegalovirus infection after transplant</a>	18/01/2023	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA861 Upadacitinib for treating active non-radiographic axial spondyloarthritis</a>	01/02/2023	Yes	
<a href="#">TA862 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments</a>	01/02/2023	Yes	
<a href="#">TA863 Somatrogen for treating growth disturbance in children and young people aged 3 years and over</a>	01/02/2023	Yes	
<a href="#">TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted</a>	01/02/2023	No	Not applicable to CWFT - Not a commissioned site
<a href="#">TA865 Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma</a>	08/02/2023	Yes	
<a href="#">TA866 Regorafenib for previously treated metastatic colorectal cancer</a>	08/02/2023	Yes	
<a href="#">TA867 Mitapivat for treating pyruvate kinase deficiency</a>	15/02/2023	No	Terminated appraisal
<a href="#">TA868 Vutrisiran for treating hereditary transthyretin-related amyloidosis</a>	15/02/2023	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA869 Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies</a>	16/02/2023	No	Terminated appraisal
<a href="#">TA870 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma</a>	22/02/2023	Yes	
<a href="#">TA871 Eptinezumab for preventing migraine</a>	01/03/2023	Yes	
<a href="#">TA872 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies</a>	28/02/2023	No	Not applicable to CWFT - Not a commissioned site
<a href="#">TA873 Cannabidiol for treating seizures caused by tuberous sclerosis complex</a>	01/03/2023	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
<a href="#">TA874 Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma</a>	01/03/2023	Yes	
<a href="#">TA875 Semaglutide for managing overweight and obesity</a>	08/03/2023	Yes	
<a href="#">TA876 Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer</a>	22/03/2023	Yes	
<a href="#">TA877 Finerenone for treating chronic kidney disease in type 2 diabetes</a>	23/03/2023	Yes	
<a href="#">TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19</a>	29/02/2023	No	Not recommended by NICE